Cargando…
Molecular Testing of Lung Cancers
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK i...
Autores principales: | Shim, Hyo Sup, Choi, Yoon-La, Kim, Lucia, Chang, Sunhee, Kim, Wan-Seop, Roh, Mee Sook, Kim, Tae-Jung, Ha, Seung Yeon, Chung, Jin-Haeng, Jang, Se Jin, Lee, Geon Kook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Pathologists and the Korean Society for Cytopathology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445209/ https://www.ncbi.nlm.nih.gov/pubmed/28427247 http://dx.doi.org/10.4132/jptm.2017.04.10 |
Ejemplares similares
-
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
por: Shim, Hyo Sup, et al.
Publicado: (2013) -
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
por: Chang, Sunhee, et al.
Publicado: (2022) -
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
por: Chang, Sunhee, et al.
Publicado: (2021) -
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
por: Kim, Hyojin, et al.
Publicado: (2014) -
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
por: Shin, Dong Hoon, et al.
Publicado: (2019)